AG
ARRY

Aperio Group’s Array Biopharma Inc ARRY Stock Holding History

Aperio Group’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-43,774
Closed -$2.03M – 3024
2019
Q2 		$2.03M Buy
43,774
+4,110
+10% +$115K 0.01% 1046
2019
Q1 		$967K Buy
39,664
+6,096
+18% +$127K ﹤0.01% 1387
2018
Q4 		$478K Buy
33,568
+8,301
+33% +$126K ﹤0.01% 1704
2018
Q3 		$384K Sell
25,267
-259
-1% -$3.97K ﹤0.01% 1905
2018
Q2 		$428K Buy
25,526
+2,572
+11% +$40.9K ﹤0.01% 1822
2018
Q1 		$375K Buy
22,954
+661
+3% +$10.6K ﹤0.01% 1836
2017
Q4 		$285K Buy
22,293
+1,500
+7% +$17.1K ﹤0.01% 1968
2017
Q3 		$256K Buy
20,793
+1,918
+10% +$17.8K ﹤0.01% 2010
2017
Q2 		$158K Sell
18,875
-1,397
-7% -$11.4K ﹤0.01% 2140
2017
Q1 		$181K Buy
20,272
+1,784
+10% +$19K ﹤0.01% 2058
2016
Q4 		$163K Buy
18,488
+1,994
+12% +$14.7K ﹤0.01% 2035
2016
Q3 		$111K Buy
16,494
+1,978
+14% +$7.65K ﹤0.01% 2017
2016
Q2 		$52K Buy
14,516
+2,282
+19% +$7.44K ﹤0.01% 1988
2016
Q1 		$36K Buy
+12,234
New +$36.7K ﹤0.01% 2006
2014
Q4 		– Sell
-10,108
Closed -$36K – 1930
2014
Q3 		$36K Buy
+10,108
New +$39.8K ﹤0.01% 1729

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Aperio Group's ARRY Position: Q3 2019 in Review

Aperio Group sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 43,774 shares — an estimated $2.03M sold.

Aperio Group first reported a position in ARRY in Q3 2014 and held it in 15 quarters. The position peaked at $2.03M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Aperio Group reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 43,774 Array Biopharma Inc shares in Q3 2019, an estimated $2.03M.
  • Aperio Group first reported a position in Array Biopharma Inc in Q3 2014 and held it in 15 quarters.
  • Aperio Group's Array Biopharma Inc position peaked at $2.03M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.